Bowel Cancer and Biomarker Research Lab

Bowel cancer, also known as colorectal cancer, is the second most common cancer in Australian men and women. It affects 1 in 13 people. It is also Australia’s second deadliest cancer, with over 5,000 people dying each year. Early detection through screening can improve survival rates, however further research is needed to help find cures and prevent the disease.

The Bowel Cancer and Biomarker Laboratory at the Kolling Institute uses advanced technologies to study the genes and proteins responsible for bowel cancers growing and spreading. Our aim is to use a patient’s own molecular information to understand the risk of bowel cancer developing and to guide treatment options. As part of our research, we are studying how to control bowel polyp growth, which are precursors to cancer. We are doing this through diet and chemotherapy drugs.

Lead

Department Head:

Prof Mark P. Molloy, PhD | Lawrence Penn Chair of Bowel Cancer Research

The University of Sydney | Northern Clinical School
Faculty of Medicine and Health
Honorary Professor | Dept. Molecular Sciences, Macquarie University
Secretary | Australasian Proteomics Society

People

Dr Jun Li PhD

Post Doctoral Research Fellow

Dr Pascal Steffen MSc, PhD

The University of Sydney, Faculty of Medicine and Health Northern Clinical School, Kolling Institute
Position: Cancer Institute NSW Early Career Fellow

Dr Matthew O’Rourke BSc, MSc, PhD

The University of Sydney | Northern Clinical School | Bowel Cancer & Biomarker Lab
Faculty of Medicine and Health
Visiting Scholar University of Technology Sydney
Elected Member NSW Royal Society

Network